Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
IonQ appoints Eric Ball, Timothy Baxter to board of directors

IonQ appoints Eric Ball, Timothy Baxter to board of directors

ReutersReuters2026/08/25 13:07
  • IonQ appointed Dr. Eric Ball, a technology finance executive, to its board.
  • Ball previously held senior finance roles at AT&T, Cisco, Flextronics, including 10 years as Oracle SVP and treasurer.
  • Timothy Baxter also joined the board; he chaired SkyWater Technology’s board before its acquisition by IonQ.
  • Baxter previously held senior leadership roles at AT&T, Sony, Samsung, including CEO of Samsung North America.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IONQ Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260825927196) on August 25, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.

Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.

智通财经2026/08/29 03:22
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.